Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | IKBKB | O14920 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | PLAT | P00750 | 1/20 | 0.45 |
| ▸ | CHUK | O15111 | 3/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31203257 | 1.00 | LMNA (0.58) | LMNABRAFIKBKBCA2CA1 | |
| Hydrochloric Acid SCHEMBL22129912 | 0.98 | LMNA (0.56) | LMNABRAFIKBKBCA2CA1 | |
| SCHEMBL8550093 | 0.93 | LMNA (0.58) | LMNABRAFIKBKBCA2CA1 | |
| SCHEMBL21962366 | 0.86 | LMNA (0.42) | LMNABRAFIKBKBCHUKAKT1 | |
| SCHEMBL9839080 | 0.82 | LMNA (0.82) | LMNACA2CA1CA9CA12 | |
| SCHEMBL24064830 | 0.81 | IMPDH2 (0.43) | IKBKBROCK1IMPDH2 | |
| SCHEMBL11146201 | 0.81 | NAPRT (0.48) | IKBKBROCK1IMPDH2 | |
| SCHEMBL30797366 | 0.81 | IMPDH2 (0.45) | AKT1ROCK1IMPDH2 | |
| SCHEMBL567493 | 0.81 | IMPDH2 (0.43) | IKBKBROCK1IMPDH2 | |
| SCHEMBL31290786 | 0.81 | IMPDH2 (0.43) | IKBKBROCK1IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286417-B2 | 1,4-diazocane compound or salt thereof | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2025-04-29 | — | — | US | claimed |
| US-20210371396-A1 | 1,4-DIAZOCANE COMPOUND OR SALT THEREOF | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2021-12-02 | — | — | US | claimed |
| EP-3900724-A1 | ISOQUINOLINESULFONYL CHLORIDE ACID ADDITION SALT AND METHOD FOR PRODUCING SAME | D. Western Therapeutics Institute, Inc. (JP) | 2021-10-27 | — | — | EP | claimed |
| EP-3875449-A1 | 1,4-DIAZOCANE COMPOUND OR SALT THEREOF | D. Western Therapeutics Institute, Inc. (JP) | 2021-09-08 | — | — | EP | claimed |
| CN-113194949-A | Isoquinoline sulfonyl chloric acid addition salt and preparation method thereof | 株式会社D.西医疗法研究所 | 2021-07-30 | — | — | CN | claimed |
| CN-113166044-A | 1, 4-diazacyclooctane compounds or salts thereof | 株式会社D.西医疗法研究所 | 2021-07-23 | — | — | CN | claimed |
| WO-2020129877-A1 | ISOQUINOLINESULFONYL CHLORIDE ACID ADDITION SALT AND METHOD FOR PRODUCING SAME | 株式会社デ・ウエスタン・セラピテクス研究所 | 2020-06-25 | — | — | WO | claimed |
| EP-2657227-B1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | WESTERN THERAPEUTICS INST INC D (JP) | 2016-04-27 | — | — | EP | claimed |
| EP-2444395-B1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | WESTERN THERAPEUTICS INST INC D (JP) | 2016-01-06 | — | — | EP | claimed |
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | claimed |
| US-8883792-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2014-11-11 | — | — | US | claimed |
| EP-2657227-A1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. Western Therapeutics Institute, Inc. (JP) | 2013-10-30 | — | — | EP | claimed |
| US-20130274269-A1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2013-10-17 | — | — | US | claimed |
| EP-2444395-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. Western Therapeutics Institute, Inc. (JP) | 2012-04-25 | — | — | EP | claimed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | claimed |
| EP-1879877-A2 | ANTIMICROBIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-23 | — | — | EP | claimed |
| WO-2006117762-A2 | ANTIMICROBIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | claimed |
| US-12286417-B2 | 1,4-diazocane compound or salt thereof | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2025-04-29 | — | — | US | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
| WO-2010146881-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | 株式会社デ・ウエスタン・セラピテクス研究所 (JP) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274269-A1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT2A1, SULT1A1, SFPQ | LMNA 4114/4885BRAF 2100/4885IKBKB 1878/4885 |
| US-12286417-B2 | 1,4-diazocane compound or salt thereof | SULT1E1, SULT1A1, SULT2A1 | LMNA 3942/4885BRAF 1725/4885IKBKB 803/4885 |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | LMNA 1798/4885BRAF 2391/4885IKBKB 645/4885 |
| US-20210371396-A1 | 1,4-DIAZOCANE COMPOUND OR SALT THEREOF | SULT1E1, SULT1A1, SULT2A1 | LMNA 3942/4885BRAF 1725/4885IKBKB 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.